

14 Jan 2020 | News

QUOTED. 14 January 2020. Marshall Stanton.

by

Medtronic said it will acquire Stingenics, which developed a differential target multiplexed spinal cord stimulation waveform, for an undisclosed figure. See what Marshall Stanton, who heads up Medtronic's pain therapy business, said about it here.

Stingenics' DTM waveform represents "the first time that a group of scientists or any company has started with a basic-science potential mechanism and developed a waveform and approach to alleviate pain based on that basis science." – Marshall Stanton, president, Medtronic's pain therapy business

- Find out more: [Medtronic Adds Stingenics' Novel Pain Therapy To Intellis Spinal Cord Stimulator](#)

[Click here](#) for a free trial of *Medtech Insight*